重组人脑利钠肽对急性心力衰竭早期肾损伤的疗效研究(1)
摘 要：目的 運用血清及尿液中性粒细胞明胶酶相关脂质运载蛋白(NAGL)、肾损伤因子-1(KIM-1)评估重组人脑利钠肽(rh-BNP)对住院急性心力衰竭患者早期肾损伤的临床疗效。方法 从我院2016年6月～2017年6月住院急性心力衰竭患者中选取SCr正常、血清及尿液NAGL、KIM-1同时升高者200例，随机分为rhBNP治疗组及常规治疗组，治疗组106例，常规组94例，同时治疗1周，于治疗结束时、结束后1周分别检测两组血清及尿液NGAL、KIM-1水平，并与治疗前比较。结果 治疗结束时两组血清NAG[(409.42±18.24)ng/ml vs(359.68±19.02)ng/ml]、尿液NAGL[(52.29±7.41)ng/ml vs (44.78±11.25)ng/ml]、血清KIM-1[(169.72±74.46)ng/ml vs (144.03±66.95)ng/ml]、尿液KIM-1[(7.39±2.96)ng/ml vs (6.38±3.01)ng/ml]水平均较治疗前下降，差异有统计学意义(P<0.05)；治疗结束后1周两组血清NAGL[(343.72±16.45)ng/ml vs (321.04±17.34)ng/ml]、尿液NAGL[(30.89±7.94)ng/ml vs (21.01±8.49)ng/ml]、血清KIM-1[(133.32±64.09)ng/ml vs (109.60±45.29)ng/ml]、尿液KIM-1[(5.78±3.03)ng/ml vs (4.50±2.27)ng/ml]水平均较治疗前下降，差异有统计学意义(P<0.05)。结论 rhBNP对于住院急性心力衰竭患者早期肾损伤有治疗价值。
, http://www.100md.com
关键词：rh-BNP；急性心力衰竭；早期肾损伤；NAGL；KIM-1
中图分类号：R541.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.11.023
文章编号：1006-1959(2018)11-0073-03
Therapeutic Effect of Recombinant Human Brain Natriuretic Peptide on Early Renal Injury in Patients with Acute Heart Failure
LI Jun，WANG Miao，LI Wei，JIANG Hai-sen，WANG Yi-wei
(Department of General Surgery，Affiliated Hospital of Chengde Medical College，Chengde 067000，Hebei，China)
, 百拇医药
Abstract：Objective To evaluate the clinical effect of recombinant human brain natriuretic peptide(rh-BNP)on early renal injury in patients with acute heart failure by using serum and urine neutrophil gelatinase related lipid carrier protein(NAGL)and renal injury factor -1(KIM-1).Methods From June 2016 to June 2017 in our hospital，patients with acute heart failure selected 200 patients with normal SCr，serum and urine NAGL and KIM-1，and were randomly divided into rhBNP treatment group and conventional treatment group.106 patients in the treatment group and 94 patients in the conventional group were treated for the same treatment for 1 week. Serum and urine levels of NGAL and KIM-1 were measured at the end of treatment and one week after treatment，respectively，and compared with those before treatment.Results At the end of treatment，serum NAGL[(409.42±18.24)ng/ml vs (359.68±19.02)ng/ml]，urine NAGL [(52.29±7.41)ng/ml vs (44.78±11.25)ng/ml]，serum KIM-1[(169.72±74.46)ng/ml vs (144.03±66.95)ng/ml]，the levels of KIM-1 in urine[(7.39±2.96)ng/ml vs (6.38±3.01)ng/ml]were significantly lower than those before treatment，the difference was statistically significant(P<0.05)；One week after treatment，serum NAGL [(343.72±16.45)ng/ml vs (321.04±17.34)]，urine NAGL[(30.89±7.94)ng/ml vs (21.01±8.49)ng/ml]，serum KIM-1[(133.32±64.09)ng/ml vs (109.60±45.29)ng/ml]，the level of urinary KIM-1[(5.78±3.03)ng/ml vs (4.50±2.27)ng/ml]decreased compared with that before treatment，and the difference was statistically significant (P<0.05).Conclusion rhBNP has therapeutic value for early renal injury in hospitalized patients with acute heart failure., http://www.100md.com(李军 王淼 李伟 蒋海森 王义围)
, http://www.100md.com
关键词：rh-BNP；急性心力衰竭；早期肾损伤；NAGL；KIM-1
中图分类号：R541.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.11.023
文章编号：1006-1959(2018)11-0073-03
Therapeutic Effect of Recombinant Human Brain Natriuretic Peptide on Early Renal Injury in Patients with Acute Heart Failure
LI Jun，WANG Miao，LI Wei，JIANG Hai-sen，WANG Yi-wei
(Department of General Surgery，Affiliated Hospital of Chengde Medical College，Chengde 067000，Hebei，China)
, 百拇医药
Abstract：Objective To evaluate the clinical effect of recombinant human brain natriuretic peptide(rh-BNP)on early renal injury in patients with acute heart failure by using serum and urine neutrophil gelatinase related lipid carrier protein(NAGL)and renal injury factor -1(KIM-1).Methods From June 2016 to June 2017 in our hospital，patients with acute heart failure selected 200 patients with normal SCr，serum and urine NAGL and KIM-1，and were randomly divided into rhBNP treatment group and conventional treatment group.106 patients in the treatment group and 94 patients in the conventional group were treated for the same treatment for 1 week. Serum and urine levels of NGAL and KIM-1 were measured at the end of treatment and one week after treatment，respectively，and compared with those before treatment.Results At the end of treatment，serum NAGL[(409.42±18.24)ng/ml vs (359.68±19.02)ng/ml]，urine NAGL [(52.29±7.41)ng/ml vs (44.78±11.25)ng/ml]，serum KIM-1[(169.72±74.46)ng/ml vs (144.03±66.95)ng/ml]，the levels of KIM-1 in urine[(7.39±2.96)ng/ml vs (6.38±3.01)ng/ml]were significantly lower than those before treatment，the difference was statistically significant(P<0.05)；One week after treatment，serum NAGL [(343.72±16.45)ng/ml vs (321.04±17.34)]，urine NAGL[(30.89±7.94)ng/ml vs (21.01±8.49)ng/ml]，serum KIM-1[(133.32±64.09)ng/ml vs (109.60±45.29)ng/ml]，the level of urinary KIM-1[(5.78±3.03)ng/ml vs (4.50±2.27)ng/ml]decreased compared with that before treatment，and the difference was statistically significant (P<0.05).Conclusion rhBNP has therapeutic value for early renal injury in hospitalized patients with acute heart failure., http://www.100md.com(李军 王淼 李伟 蒋海森 王义围)